BioCryst Pharmaceuticals (BCRX) closed the last trading session at $7.95, gaining 4.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $14.27 indicates a 79.5% upside potential.The mean estimate comprises 11 short-term price targets with a standard deviation of $6.71. While the lowest estimate of $7 indicates a 12% decline from the current price level, the most optimistic analyst e ...